Takeda Pharmaceutical Company Limited Stock Sao Paulo
Stocks
TAKP34
BRTAKPBDR006
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Sao Paulo
10:51:49 2026-10-27 EDT
|
5-day change | 1st Jan Change | ||
| 109.00 BRL | +4.31% |
|
+9.55% | +31.07% |
| 10-25 | Takeda Pharmaceutical Eyes 2027 Japan Filing for Gastric Cancer Treatment | MT |
| 10-25 | Takeda to seek Japan approval for gastric cancer drug next year | RE |
| Market Cap | 10,230B 346B 64.8B 58.16B 53.7B 48.69B 91.01B 6,155B 92.13B 644B 256B 3,226B 243B 238B | P/E 2027 * |
50.8x | P/E 2028 * | 32.2x |
|---|---|---|---|---|---|
| Enterprise Value | 14,138B 479B 89.55B 80.37B 74.21B 67.29B 126B 8,506B 127B 890B 353B 4,458B 336B 329B | EV / Sales 2027 * |
3.01x | EV / Sales 2028 * | 2.91x |
| Free-Float |
99.18% | Yield 2027 * |
3.19% | Yield 2028 * | 3.25% |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 day | +4.31% | ||
| 1 week | +9.55% | ||
| Current month | +10.02% | ||
| 1 month | +10.02% | ||
| 3 months | +32.41% | ||
| 6 months | +21.84% | ||
| Current year | +31.07% |
| 1 week | 104.5 |  | 109 |
| 1 month | 90 | | 109 |
| Current year | 76.32 | | 109 |
| 1 year | 70.8 | | 109 |
| 3 years | 66.46 | | 109 |
| 5 years | 66.1 | | 109 |
| 10 years | 66.1 | | 109 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 2024-12-31 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 2024-03-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 48 | 2022-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 61 | 2015-05-31 |
Steven Gillis
BRD | Director/Board Member | 73 | 2018-12-31 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 2024-05-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.31% | +9.55% | - | - | 65.39B | |
| +0.22% | -0.14% | +55.12% | +128.82% | 1,140B | |
| +0.91% | +3.61% | +41.21% | +84.57% | 641B | |
| -0.12% | -0.93% | +25.59% | +106.14% | 507B | |
| +0.63% | +2.33% | +49.21% | +67.82% | 383B | |
| +0.86% | -4.37% | +61.16% | +37.93% | 347B | |
| +1.02% | +1.80% | +24.84% | +53.75% | 293B | |
| -0.25% | +1.62% | +2.20% | +26.65% | 266B | |
| +0.75% | +2.05% | +53.85% | +71.25% | 240B | |
| +0.25% | +1.64% | +32.05% | +107.62% | 197B | |
| Average | +0.86% | +2.92% | +38.36% | +76.06% | 445.98B | |
| Weighted average by Cap. | +0.50% | +2.98% | +42.20% | +88.48% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,702B 159B 29.78B 26.73B 24.68B 22.38B 41.83B 2,829B 42.34B 296B 118B 1,483B 112B 109B | 4,796B 162B 30.38B 27.26B 25.17B 22.83B 42.66B 2,885B 43.19B 302B 120B 1,512B 114B 112B |
| Net income | 196B 6.65B 1.24B 1.12B 1.03B 934M 1.75B 118B 1.77B 12.36B 4.91B 61.91B 4.67B 4.57B | 323B 10.94B 2.05B 1.84B 1.7B 1.54B 2.87B 194B 2.91B 20.33B 8.07B 102B 7.68B 7.52B |
| Net Debt | 3,907B 132B 24.75B 22.21B 20.51B 18.6B 34.76B 2,351B 35.19B 246B 97.66B 1,232B 92.9B 90.91B | 3,705B 125B 23.47B 21.06B 19.45B 17.63B 32.96B 2,229B 33.36B 233B 92.59B 1,168B 88.08B 86.2B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-27 | R$109.00 | +4.31% | 15 |
| 26-10-26 | R$104.50 | +5.03% | 4 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
- TAKP34 Stock
Select your edition
All financial news and data tailored to specific country editions
